Tremelimumab for Cholangiocarcinoma

"Globally, there are 340 ongoing studies involving Tremelimumab in 1327 cities and 58 countries. This drug was first trialed back in 2007 by AstraZeneca with 37 participants for Phase 2 approval. Over the last 14 years, 168 of these trials have been finalized."

"Tremelimumab has shown some promise in terms of safety, earning a score of 2. Nonetheless, there is yet to be any clinical data demonstrating its efficacy on humans."

"The records on clinicaltrials.gov indicate that this trial is no longer in need of recruits. The study first went live on July 5th 2016 and was last updated March 1st 2022, but there are 3229 other trials actively seeking patients right now."

"Currently, 340 live clinical trials are researching Tremelimumab worldwide. Of those, 52 have entered Phase 3 testing and the majority of these can be found in Cordoba, Texas. However, there is a total of 13083 locations hosting studies for this medication."

"Tremelimumab is a valuable treatment option for many patients with unresectable stage iii non-small cell lung cancer, as well as those suffering from previously untreated metastatic ureter urothelial carcinoma and advanced directives."

"Unfortunately, this clinical trial is not presently enrolling new patients. It was initially listed on July 5th 2016 with the most recent update occurring in March 2021. Fortunately, there are 2889 studies seeking cholangiocarcinoma patients and 340 trials conducting research into Tremelimumab that are actively recruiting participants."